Delta Asset Management LLC TN boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 0.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,248 shares of the medical instruments supplier’s stock after purchasing an additional 474 shares during the quarter. Becton Dickinson and makes up 2.9% of Delta Asset Management LLC TN’s investment portfolio, making the stock its 12th biggest holding. Delta Asset Management LLC TN’s holdings in Becton Dickinson and were worth $20,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently modified their holdings of the company. Harvest Group Wealth Management LLC purchased a new position in shares of Becton Dickinson and in the 1st quarter valued at about $25,000. Hexavest Inc. purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $28,000. Lipe & Dalton purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $28,000. Pinnacle Financial Partners Inc. purchased a new position in shares of Becton Dickinson and in the 1st quarter valued at about $29,000. Finally, RPG Investment Advisory LLC purchased a new position in shares of Becton Dickinson and in the 1st quarter valued at about $32,000. Institutional investors own 84.85% of the company’s stock.
In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 275 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $235.00, for a total transaction of $64,625.00. Following the completion of the sale, the executive vice president now directly owns 16,482 shares of the company’s stock, valued at approximately $3,873,270. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samrat S. Khichi sold 16,085 shares of the stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the sale, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The disclosure for this sale can be found here. Insiders have sold a total of 21,154 shares of company stock valued at $4,955,775 over the last ninety days. 0.12% of the stock is owned by insiders.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.91 EPS. Equities research analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.27%. Becton Dickinson and’s payout ratio is 27.97%.
BDX has been the topic of a number of recent analyst reports. BMO Capital Markets dropped their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a report on Friday, May 10th. KeyCorp restated an “overweight” rating and set a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a research note on Friday, May 10th. Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target on the stock in a research note on Monday, May 13th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $266.00 price target (down previously from $267.00) on shares of Becton Dickinson and in a research note on Tuesday. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $264.27.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Leveraged Buyout (LBO)
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.